Zogenix (ZGNX) Prices 8.52M Share Common Offering at $23/Sh

Zogenix, Inc. (NASDAQ: ZGNX) announced today that it has priced an underwritten public offering of 8,520,000 shares of its common stock at a price to the public of $23.50 per share. The gross proceeds to Zogenix from the offering, before underwriting discounts and commissions and offering costs, are expected to be approximately $200.2 million. Zogenix has granted the underwriters a 30-day option to purchase up to an additional 1,278,000 shares of common stock. All of the shares to be sold in the offering are being sold by Zogenix. The offering is expected to close on or about March 6, 2020, subject to satisfaction of customary closing conditions.

Zogenix intends to use the net proceeds from the proposed offering to support its activities related to the potential commercialization of FINTEPLA® for the treatment of Dravet syndrome, submission of regulatory applications in the United States and the European Union for FINTEPLA for the treatment of Lennox-Gastaut syndrome, funding of future clinical trials of FINTEPLA for other indications, continuing development and activities related to the potential commercialization of MT1621 for the treatment of thymidine kinase 2 deficiency, and for working capital and general corporate purposes.

SVB Leerink and Stifel are acting as joint book-running managers for the offering.

You May Also Be Interested In

• Eos Energy gets $125M from Hudson Bay for Frontier Power USA
• Stifel on Digital Realty Trust (DLR): 'confidence in sustained growth in digital infrastructure'
• Markel names Bhavik Desai as MD of PFR & Cyber in London